In this video, Austin Smith interviews Jim Mueller, author of the Fool's premium report on Express Scripts. Jim thinks the company is a buy for three reasons:
- $290 billion of drugs are coming off-patent over the next five years, and the company can benefit from selling more profitable generics.
- The U.S. and European populations are aging.
- Obamacare will bring many more people onto the rolls.
For more details, check out the video.
Austin Smith owns shares of Pfizer. Jim Mueller has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.